DJIA 15,112.19 -206.04 -1.35%
NASDAQ 3,443.20 -38.98 -1.12%
S&P 500 1,628.93 -22.88 -1.39%
market minute promo

Amgen, Inc.

NASDAQ: AMGN

99.18 -2.32 (-2.29%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

AMGN $99.18 -2.29%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $101.69
Previous Close $101.50
Daily Range $99.15 - $102.00
52-Week Range $70.88 - $114.95
Market Cap $74.4B
P/E Ratio 17.15
Dividend (Yield) $1.88 (1.9%)
Ex-Dividend Date
Dividend Pay Date
05/14/13
06/07/13
Volume 3,759,058
Average Daily Volume 3,328,655
Current FY EPS $7.20

Sector

Healthcare

Industry

Drugs

Amgen, Inc. (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/

News & Commentary

This Blockbuster Biologic May Face a Steep Cliff

Neulasta generated sales north of $4 billion for Amgen in 2012, but generic competition is brewing on two continents.

Amgen In Focus

Amgen Xgeva Label Expanded - Analyst Blog

Top Treatments for High Cholesterol

There's an investment opportunity, but it's going to take time to play out.

American Generics Can't Touch This $8 Billion Drug (Yet)

A quirk in patent laws handed Enbrel exclusivity through 2028, but the competition isn't wasting any time.

5 Stocks Raising The Drugs Industry Higher

Barron's Recap: Midyear Roundtable

Today's Market: Biotech And Cable M&A The Big Stories

Taking Care Of Yourself And Your Property Through These Stocks

3 Winners and 2 Losers From Rigel's Failure

Having your top drug candidate fail a late-stage trial is never a good thing, especially if you're a developmental-stage company. Fortunately for Rigel, it's not all bad news.

See More AMGN News...

AMGN's Top Competitors

AMGN $99.18 (-2.29%)
Current stock: AMGN
GILD $50.60 (-2.58%)
Current stock: GILD
CELG $116.89 (-2.79%)
Current stock: CELG
$0.00 (0.00%)
Current stock: